346688-38-8CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1YGKUEOZJFIXDGI-UHFFFAOYSA-NACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington’s disease, Parkinson’s disease and schizophrenia respectively. ACR-16 is a dopamine stabilizer. ACR-16 is also being studied in other psychiatric and neurologic diseases.
346688-38-8DTXSID90188225CHEMBL596802Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
N - Nervous system
QN - Nervous system
ACR16 belongs to a novel class of drugs, characterised as dopaminergic stabilisers, CNS active compounds that can both enhance and counteract dopaminergic effects in the brain depending on the initial level of dopaminergic activity. ARC16 works to "smooth" the many functions of this neurotransmitter chemical in striatum and other areas of the brain. Thus they have the ability to stabilize behavioural and motor disturbances caused by neurological and psychiatric disorders. They do this in pathological states without compromising normal thought processes or motor functions.
Verwenden4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine is a new modulator of dopamine neurotransmission. Dopamine is a neurotransmitter in the brain. Drugs that act at central dopamine receptors are commonly used in the treatment of neurologic and psychiatric disorders.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…